GHGiang Truong Ho

Giang Truong Ho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giang Truong Ho has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of the sensitivity and specificity of monoclonal antibodies for detecting the thioredoxin antigen in hepatocellular carcinoma patients

    by Duong Quang Huy, Ho Truong Giang, Nguyen Thi Diem, Vo Thi Bich Thuy

    The objective of this study was to evaluate the sensitivity and specificity of the monoclonal antibody of thioredoxin (mAb-TXN) for detecting the thioredoxin (TXN) antigen in serum samples from patients with hepatocellular carcinoma (HCC). To achieve this, the mAb-TXN, generated from hybridoma cells, was utilized to optimize the conditions for an indirect ELISA immunoassay. The sensitivity, specificity, positive predictive value, and negative predictive value of the assay were evaluated on the basis of stored patient medical records. The results showed that indirect ELISA using mAb-TXN exhibited a sensitivity of 93.61%, a specificity of 96%, a positive predictive value of 97.77%, and a negative predictive value of 88%. In conclusion, mAb-TXN is a valuable tool for detecting TXN antigens in serum samples from HCC patients, offering high sensitivity and specificity for clinical application.

  • Open Access

    Development of an indirect ELISA to detect antigens using DNA origami nanoantenna labeled specific monoclonal antibodies

    by Huy Quang Duong, Khai Xuan Nguyen, Giang Truong Ho, Minh Ngoc Nghiem, Thuy Thi Bich Vo

    This research examines the development of an indirect ELISA to detect antigens using DNA origami nanoantenna-labeled specific monoclonal antibodies. Hepatocellular carcinoma (HCC) is one of the five most common cancers and the second leading cause of cancer-related death worldwide. More than 60% of cases are detected in the late stage, with the absence of specific symptoms in the early stage of the disease. Adding measurements of AFP (Alpha-Fetoprotein), TXN (Thioredoxin), and DCP (Des-γ-Carboxy Prothrombin) has the potential to improve the accuracy of diagnosing hepatocellular carcinoma. DNA origami technology is revolutionizing the forefront of cancer diagnostics, particularly for HCC. In this study, an indirect enzyme-linked immunosorbent assay (ELISA) method targeting the assessment of the effectiveness of specific monoclonal antibody-conjugated DNA origami particles was developed. The results of DNA origami folding into complex nanostructures and labeled biomarkers like AFP, DCP, and TXN have explored the high specificity and sensitivity for targeting HCC. We found the cut-off values for AFP, DCP, and TXN to be 0.132, 0.156, and 0.150, respectively. The coefficients of variation for samples remained consistently under 10%, indicating the method's high degree of stability and reproducibility. This innovation, combined with biomarkers, promised in early HCC detection, holds the potential to significantly enhance patient outcomes in the fight against liver cancer. The platform also has enormous potential for advancing personalized medicine.